NCT07567690Active, not recruiting
Real-world Immunogenicity of Anti-IL5/5a Antibody
A Prospective Observational Study of Biologic Treatment and Outcomes in Patients With Severe Asthma (BREATH)
Source: ClinicalTrials.gov · Last updated 5 May 2026
Brief summary (registry, in English)
This study aims to evaluate the immunogenicity of the drug by measuring anti-drug antibody (ADA) formation and titers. The presence of ADAs will be assesses to determine their potential impact on the drug's efficacy and safety.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 100 (estimated)
- First submitted
- 22 Apr 2026
- Start date
- 19 Aug 2025
- Primary completion date
- 30 Nov 2026
- Lead sponsor
- Samsung Medical Center
- Diseases
- Asthma
- NCT number
- NCT07567690
What you commit to
- Study type: Observational
- Planned participants: 100
- From 19 Aug 2025 to the primary completion date, 30 Nov 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of hypersensitivity reactions to biologics (anti IL5 or IL5Ra)
Who the study is looking for
- Patients with severe asthma
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Samsung Medical Center Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.